Equities

Amplia Therapeutics Ltd

Amplia Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.135
  • Today's Change0.036 / 36.36%
  • Shares traded803.53k
  • 1 Year change+65.36%
  • Beta1.1655
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.

  • Revenue in AUD (TTM)4.44m
  • Net income in AUD-4.50m
  • Incorporated2013
  • Employees1.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BPH Energy Ltd843.69k4.56m14.47m2.00k3.120.4674--17.150.00390.00390.00080.02570.0333--11.41--17.985.1218.585.50----539.93238.65----0.0029--177.4824.84433.96------
Medlab Clinical Ltd366.64k-3.94m15.04m14.00------41.02-1.73-1.730.1606-0.30680.1069--5.82---103.72-55.07-240.52-69.7584.7752.86-970.74-335.43---342.19-----28.90-29.8318.55---30.00--
Rhythm Biosciences Ltd52.28k-6.86m15.41m----17.77--294.82-0.0301-0.03010.00020.00350.01141.911.02---148.83-134.13-199.13-168.97-4,946.29-1,807.84-13,115.47-9,433.231.58-1,750.400.1589---77.10-18.0116.56---5.69--
BTC Health Ltd16.36k1.06m15.56m1.0013.913.1514.74950.970.00350.00350.000050.01530.004------26.09-21.2227.32-22.60----6,450.37-3,306.65----0.00--23.38-38.62110.38------
Alterity Therapeutics Ltd268.42k-19.12m15.96m11.00--1.14--59.46-0.0052-0.00520.000070.00260.0115--0.1307---82.18-56.58-103.97-66.91-----7,124.45-22,925.08----0.0114--1,532.7319.85-38.51---4.01--
Biotron Ltd1.65m-3.44m18.95m4.00------11.52-0.0038-0.00380.0018-0.00030.7108-------148.49-77.12-234.15-92.61-120.34-127.14-208.89-238.85--------14.948.931.61------
Invion Ltd3.74m-5.63m20.30m8.00--1.37--5.42-0.0009-0.00090.00060.00220.217--2.65---32.63-19.46-34.28-20.50-----150.33-70.20----0.00---9.54-0.7235-248.51--171.96--
Tryptamine Therapeutics Ltd1.21m-4.32m21.78m----3.24--18.04-0.0162-0.01620.00390.00620.2368-------84.69---120.26-------357.70-----21.620.00--------------
LBT Innovations Limited1.31m-3.74m23.13m17.00--13.20--17.66-0.0032-0.00320.0010.00110.17120.09592.52---48.89-34.86-78.03-38.5388.63---285.50-513.872.56-12.080.5686---39.04-14.7183.40---69.50--
Bioxyne Ltd9.33m-12.80m26.61m16.00--7.38--2.85-0.007-0.0070.00640.00180.76463.7810.33---106.39-56.02-134.91-72.4636.4440.00-139.14-85.521.18-40.410.0526--80.7034.32-559.75--50.56--
Amplia Therapeutics Ltd4.44m-4.50m27.21m1.00--1.73--6.13-0.0226-0.02260.02220.05720.2647--2.05---26.86-25.13-32.90-27.42-----101.48-206.74----0.122--286.42144.8127.86---6.91--
Tissue Repair Ltd548.09k-4.14m29.02m----1.61--52.95-0.0684-0.06840.00910.29830.02620.001.22---19.81-24.20-20.72-25.29100.00---755.00-10,570.1414.34--0.00--4,842.86--0.8698------
Noxopharm Ltd2.41m-3.58m29.22m1.00k--5.32--12.14-0.0086-0.00860.00820.01880.2847--2.00---42.31-43.24-48.67-52.58-----148.64-170.07---------60.33-9.3776.24------
Prescient Therapeutics Ltd687.57k-8.24m32.21m3.00--1.78--46.85-0.0102-0.01020.00090.02240.0284--3.31---33.97-28.85-37.31-30.66-----1,198.14-2,096.39---288.970.018--49.7756.99-17.61------
Cynata Therapeutics Ltd417.71k-9.74m34.33m0.00--4.73--82.18-0.0543-0.05430.00230.04020.0305--1.85---71.18-39.49-81.37-42.96-----2,332.89-515.32----0.00--18.3816.5131.75------
Data as of Sep 20 2024. Currency figures normalised to Amplia Therapeutics Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

5.53%Per cent of shares held by top holders
HolderShares% Held
Pengana Capital Ltd.as of 31 May 202415.20m5.53%
Data from 31 May 2024 - 31 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.